Developing a best in class alternative vaccine technology to protect people who need it the most against neglected and emerging infectious diseases
EdJen Biotech, the ICW Ventures project named in honor of Edward Jenner, a pioneer of vaccinology, is a disruptive vaccine company created to rapidly address global vaccination needs through advanced peptide technology.
EdJen was founded to creatively challenge current thought conventions and methodologies in order to re-invent and revolutionize the vaccine world by generating affordable and accessible vaccines for everyone.
EdJen Biotech is developing a next generation vaccine platform that improves efficacy, greatly reduces side effects, lowers production and retail cost, and shortens manufacturing time.
Through AI-informed discovery and novel formulation approaches, EdJen can respond to emerging pandemic threats in as little as 100 days. Therefore, with only small portions of the pathogen, EdJen can deliver a synthetic vaccine that generates responses across multiple pathogenic proteins resulting in robust protection.
EdJen has demonstrated the viability of this approach with previous research in Influenza, Zika, Measles, Mumps, and Vaccinia, and is now developing a Mpox vaccine as our proof-of-concept pathogen, given its high pandemic potential and continued spread and mutation.
EdJen Biotech is built upon on two decades of scientific research by a highly talented team dedicated to identify peptide-based immune responses.
EdJen Biotech is harnessing partnerships with the most recognized public health companies to make this scientific platform not only a breakthrough innovation but also an equitable vaccine solution.
Other innovative projects
E-Star Biotech
Passionately dedicated to equitable care and the development of medicine in support of populations that have been overburdened with disease.
GENOMADIX